… response to gefitinib [19,20]. This review concentrates on the past clinical studies of gefitinib
and … The feasibilities of toxicity or schedule were reported in a Phase I study of concurrent …

… We conducted a randomized phase II study, NEJ005, that compared the concurrent use of …
Meanwhile, liver toxicity was more frequent in the gefitinib group (the rate of grade ≥ 3 toxicity …

… to supportive care improves survival in advanced non-small-cell lung cancer: a systematic
review and meta-analysis of individual patient data from 16 randomized controlled trials. …

… toxicity grade within 7 days after the interruption of gefitinib treatment. Gefitinib treatment was
interrupted for any grade 2 toxicity … A phase I/II clinical study of gefitinib + radiation for newly-…

… Although irradiation pneumonia did not cause any treatment-related deaths among participants
in our study, the pulmonary toxicity associated with EGFR-TKIs is a cause for concern. …

… Pre-clinical studies have demonstrated that gefitinib-resistant NSCLC cells are more sensitive
… Our study showed that combining CPT-11 and gefitinib is feasible without adverse toxicity. …

… We already performed the phase I clinical trial to determine recommended phase II dosing
(… could be evaluated for efficacy and toxicity in this study. Progressive disease was confirmed …

… I and II gefitinib monotherapy trials, with particular emphasis on data from pretreated patients
with NSCLC. Supportive data from subsequent clinical studies, … with haematological toxicity, …

… Interruptions due to toxicity were reported in 10 patients (12%) in the gefitinib arm versus 1
… HQ lung group clinical research physician for her contributions to the study. The authors are …

… Gefitinib has clinical activity as monotherapy in SCCHN. Dose escalation of gefitinib is feasible
and may increase skin toxicity… 2 or greater skin toxicity on gefitinib would be more likely to …